CN113080470A - Composition beneficial to intestinal regulation and preparation method thereof - Google Patents
Composition beneficial to intestinal regulation and preparation method thereof Download PDFInfo
- Publication number
- CN113080470A CN113080470A CN202110393809.5A CN202110393809A CN113080470A CN 113080470 A CN113080470 A CN 113080470A CN 202110393809 A CN202110393809 A CN 202110393809A CN 113080470 A CN113080470 A CN 113080470A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- composition
- weight
- parts
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 26
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 78
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 78
- 238000000855 fermentation Methods 0.000 claims abstract description 42
- 230000004151 fermentation Effects 0.000 claims abstract description 32
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 24
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 23
- 239000003094 microcapsule Substances 0.000 claims abstract description 23
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 22
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 18
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 18
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 18
- 239000000661 sodium alginate Substances 0.000 claims abstract description 18
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- 239000012528 membrane Substances 0.000 claims abstract description 15
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 claims abstract description 10
- 230000028327 secretion Effects 0.000 claims abstract description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 3
- 239000000835 fiber Substances 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 28
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 241001052560 Thallis Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 230000001007 puffing effect Effects 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 12
- 229940039696 lactobacillus Drugs 0.000 abstract description 12
- 210000004379 membrane Anatomy 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 7
- 230000004888 barrier function Effects 0.000 abstract description 5
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 5
- 241000186000 Bifidobacterium Species 0.000 description 13
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000004402 polyphenol group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition beneficial to intestinal regulation, which comprises active components, wherein the active components comprise inulin, xylooligosaccharide, oat dietary fiber, a cassia seed extract and a lactobacillus reuteri fermentation product, and the lactobacillus reuteri fermentation product is obtained by the following steps: obtaining the lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain the lactobacillus reuteri fermentation product. The composition for regulating intestinal tract also comprises a membrane component, wherein the membrane component comprises chitosan and sodium alginate, and the membrane component is coated outside the active component to form a microcapsule. The composition can enhance the barrier function of intestinal epithelium and promote the proliferation of intestinal original lactobacillus.
Description
Technical Field
The invention relates to the technical field of food, in particular to a composition beneficial to intestinal regulation and a preparation method thereof.
Background
The intestinal tract is an important digestive organ of a human body, is the longest section in a digestive tube, has the most important function, and is also the largest detoxifying organ. The intestinal tract is about 6-10 meters long, the fold unfolding area reaches 200 square meters, the intestinal tract toxin is a main source of body toxin, and accumulation of intestinal toxin in the intestinal tract can cause intestinal diseases such as intestinal cancer, appendicitis, hemorrhoids, enteritis, constipation, body odor, halitosis and the like, and can also cause various problems such as weight increase, belly growth, dark and rough skin and the like.
In recent years studies have shown that impaired intestinal mucosal barrier is a significant cause of decreased intestinal motility. When the intestinal mucosa barrier is damaged, the intestinal contents are not completely digested, a large amount of incompletely metabolized toxins are accumulated in the intestinal tract, the propagation of harmful flora in the intestinal cavity is increased, the proliferation of beneficial flora is reduced, and finally the intestinal motility is reduced.
Disclosure of Invention
The invention aims to provide a composition which can enhance the barrier effect of intestinal epithelium and is beneficial to the proliferation of intestinal original lactobacillus and is beneficial to intestinal regulation.
In order to achieve the purpose, the invention adopts the technical scheme that: the composition for facilitating intestinal regulation comprises active components, wherein the active components comprise 40-60 parts by weight of inulin, 10-30 parts by weight of xylo-oligosaccharide, 8-15 parts by weight of oat dietary fiber, 10-15 parts by weight of semen cassiae extract and 5-12 parts by weight of lactobacillus reuteri fermentation product, and the method for obtaining the lactobacillus reuteri fermentation product comprises the following steps: obtaining the lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain the lactobacillus reuteri fermentation product.
Preferably, the composition for regulating intestinal tract also comprises a membrane component, wherein the membrane component comprises chitosan and sodium alginate, and the membrane component is coated outside the active component to form a microcapsule.
Preferably, the oat dietary fiber is expanded oat dietary fiber.
The invention also aims to provide a preparation method of the composition for facilitating intestinal regulation, which has simple operation steps and high reproducibility.
In order to achieve the purpose, the invention adopts the technical scheme that: a preparation method of a composition for facilitating intestinal regulation comprises the following steps:
1) extraction of lactobacillus reuteri fermentation: obtaining lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain lactobacillus reuteri fermentation product;
2) primary curing of active ingredients: adding water into a mixture of 5-12 parts by weight of lactobacillus reuteri fermentation product and 10-30 parts by weight of xylo-oligosaccharide until the mixture is completely dissolved to obtain a first mixed solution, extruding and puffing 8-15 parts by weight of oat dietary fiber, drying to obtain puffed fiber, adding the first mixed solution into the puffed fiber, and adding N2Reacting under the environment until the reaction is dried to obtain active expanded fiber;
3) microencapsulation: and mixing the activated swelling fiber with 40-60 parts by weight of inulin, 10-15 parts by weight of cassia seed extract, chitosan, sodium alginate, water and an edible surfactant, and spray-drying to obtain the microcapsule beneficial to intestinal regulation.
Preferably, salmonella enteritidis and lactobacillus reuteri are simultaneously inoculated in a lactobacillus culture medium for culture, then, viable lactobacillus reuteri is separated from mixed bacteria, the separated lactobacillus reuteri is subjected to expanded culture and then filtered to obtain thalli, the obtained lactobacillus reuteri is subjected to anaerobic fermentation and then filtered to obtain thalli, a Tris-HCl buffer solution is added into the obtained thalli, a supernatant is obtained by centrifugation, and the obtained supernatant is filtered by a semipermeable membrane to obtain a filtrate.
Preferably, in the extraction step of the lactobacillus reuteri fermented product, the harvested filtrate is freeze-dried for preservation.
Preferably, in the active ingredient primary curing step, N is2The pressure of the pressure sensor is 0.4-1 MPa.
Preferably, the step of adding the raw material in the microencapsulation step is: adding inulin, oat dietary fiber, semen Cassiae extract and edible surfactant into water, mixing, adding chitosan, sodium alginate and active puffing fiber, and mixing.
Preferably, in the microencapsulation step, chitosan, sodium alginate and active bulking fiber are added and uniformly mixed, and then the mixture is stood for 20-40 min and then spray-dried.
Preferably, in the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 40 to 80 mesh.
Compared with the prior art, the invention has the beneficial effects that: because the chitosan and the sodium alginate which form the film on the outer surface of the microcapsule have good hygroscopicity, the microcapsule exposed in the intestinal tract has good viscosity, and the contact time of the active components with the intestinal tract epithelium and mucus is prolonged. The lactobacillus reuteri fermentation product in the active component can effectively activate Akt genes of intestinal epithelial cells, promote the growth of the intestinal epithelial cells and inhibit TNF-alpha induced epithelial cell necrosis, thereby protecting the tight connection structure of the epithelial cells and ensuring the integrity of an intestinal mucosa barrier. Meanwhile, the lactobacillus reuteri fermentation product can induce intestinal epithelial cells to generate adhesin receptors corresponding to lactobacillus and bifidobacterium, and the adhesion of intestinal native lactobacillus and bifidobacterium to the intestinal epithelial cells is improved. Abundant lactobacillus reuteri leavening and xylo-oligosaccharide are attached to the active puffed fiber at the same time, and the lactobacillus reuteri leavening improves the adhesiveness of intestinal native lactobacillus and bifidobacterium with intestinal epithelial cells, and the xylo-oligosaccharide promotes the proliferation activity of the adhered lactobacillus and bifidobacterium.
Detailed Description
The present invention will be described in further detail with reference to examples.
Example 1:
the composition for regulating intestinal tracts comprises active components, wherein the active components comprise 45 parts by weight of inulin, 16 parts by weight of xylo-oligosaccharide, 12 parts by weight of oat dietary fiber, 11 parts by weight of semen cassiae extract and 8 parts by weight of lactobacillus reuteri fermentation product, and the oat dietary fiber is puffed oat dietary fiber. The method for obtaining the lactobacillus reuteri fermentation product comprises the following steps: obtaining the lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain the lactobacillus reuteri fermentation product.
The composition for regulating intestinal tract also comprises a membrane component, wherein the membrane component comprises chitosan and sodium alginate, and the membrane component is coated outside the active component to form a microcapsule.
A preparation method of a composition for facilitating intestinal regulation comprises the following steps:
1) extraction of lactobacillus reuteri fermentation: obtaining lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain lactobacillus reuteri fermentation product;
2) primary curing of active ingredients: adding water into a mixture of 8 parts by weight of lactobacillus reuteri leavening and 16 parts by weight of xylo-oligosaccharide until the mixture is completely dissolved to obtain a first mixed solution, extruding and puffing 12 parts by weight of oat dietary fiber, drying to obtain puffed fiber, adding the first mixed solution into the puffed fiber, and adding N2Reacting under the environment until the reaction is dried to obtain active expanded fiber;
3) microencapsulation: and mixing the activated swelling fiber with 45 parts by weight of inulin, 11 parts by weight of semen cassiae extract, chitosan, sodium alginate, water and an edible surfactant, and spray-drying to obtain the microcapsule beneficial to intestinal regulation. The resulting microcapsules are placed in an enteric coating.
In the extraction step of the lactobacillus reuteri fermentation product, salmonella enteritidis and lactobacillus reuteri are simultaneously inoculated in a lactobacillus culture medium for culture, then, the viable lactobacillus reuteri is separated from mixed bacteria, the separated lactobacillus reuteri is subjected to expanded culture and then filtered to obtain thalli, the obtained lactobacillus reuteri is subjected to anaerobic fermentation and then filtered to obtain thalli, a Tris-HCl buffer solution is added into the obtained thalli, the supernatant is obtained by centrifugation, and the obtained supernatant is filtered by a semipermeable membrane to obtain filtrate.
In the extraction step of the lactobacillus reuteri fermented product, the harvested filtrate is freeze-dried for preservation.
In the initial curing step of the active ingredient, N2The pressure of (2) is 0.7 MPa.
The addition steps of the raw materials in the microencapsulation step are as follows: adding inulin, oat dietary fiber, semen Cassiae extract and edible surfactant into water, mixing, adding chitosan, sodium alginate and active puffing fiber, and mixing.
In the microencapsulation step, chitosan, sodium alginate and active swelling fiber are added and mixed evenly, and then the mixture is stood for 35min and then spray-dried.
In the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 60 meshes.
After the oat dietary fiber is extruded, puffed and dried, the oat dietary fiber has rich pore structures, hydrogen bonds among fiber molecules are broken, polyphenol structures are exposed, and more carboxyl groups are generated. After the puffed fiber is mixed with the lactobacillus reuteri leavening and the xylo-oligosaccharide, the micromolecular lactobacillus reuteri leavening and the xylo-oligosaccharide enter a pore structure of the puffed fiber, amino in lactobacillus reuteri leavening molecules and carboxyl on the puffed fiber generate hydrogen bonds, and hydroxyl in the xylo-oligosaccharide molecules and the carboxyl on the puffed fiber generate hydrogen bonds. At the same time in N2Under the environment, the reactive groups on the expanded fiber, the lactobacillus reuteri fermentation product and the xylo-oligosaccharide can be prevented from reacting with oxygen in the air, and the number of the hydrogen bonds can be ensured so as to improve the stability of the lactobacillus reuteri fermentation product and the xylo-oligosaccharide in the expanded fiber. High voltage N2The environment can provide power for the lactobacillus reuteri leavening and the small gap of the xylo-oligosaccharide entering the deep of the puffed fiber, and the stability of the lactobacillus reuteri leavening and the xylo-oligosaccharide puffed fiber can be further improved, so that the elution amount of the lactobacillus reuteri leavening and the xylo-oligosaccharide in the microencapsulation step is greatly reduced.
After the microcapsule of the invention is swallowed, the microcapsule can smoothly reach the intestinal tract due to the arrangement of the enteric coating outside the microcapsule. Because the chitosan and the sodium alginate which form the film on the outer surface of the microcapsule have good hygroscopicity, the microcapsule exposed in the intestinal tract has good viscosity, and the contact time of the active components with the intestinal tract epithelium and mucus is prolonged. The lactobacillus reuteri fermentation product in the active component can effectively activate Akt genes of intestinal epithelial cells, promote the growth of the intestinal epithelial cells and inhibit TNF-alpha induced epithelial cell necrosis, thereby protecting the tight connection structure of the epithelial cells and ensuring the integrity of an intestinal mucosa barrier. Meanwhile, the lactobacillus reuteri fermentation product can induce intestinal epithelial cells to generate adhesin receptors corresponding to lactobacillus and bifidobacterium, and the adhesion of intestinal native lactobacillus and bifidobacterium to the intestinal epithelial cells is improved. Abundant lactobacillus reuteri leavening and xylo-oligosaccharide are attached to the active puffed fiber at the same time, and the lactobacillus reuteri leavening improves the adhesiveness of intestinal native lactobacillus and bifidobacterium with intestinal epithelial cells, and the xylo-oligosaccharide promotes the proliferation activity of the adhered lactobacillus and bifidobacterium.
Inulin is a natural water-soluble dietary fiber, hardly hydrolyzed and digested by gastric acid, and is utilized only in the colon by beneficial microorganisms, thereby improving the intestinal environment. The proliferation degree of bifidobacteria depends on the number of initial bifidobacteria in the large intestine of a human body, and when the number of initial bifidobacteria is reduced, the proliferation effect is obvious after inulin is used. Secondly, after the inulin is ingested, the gastrointestinal peristalsis can be enhanced, the gastrointestinal function can be improved, the digestion and the appetite can be increased, and the organism immunity can be improved. The oat dietary fiber can promote intestinal peristalsis, and the semen Cassiae extract has effects of loosening bowel to relieve constipation. The active ingredients of the invention cooperate with each other to greatly improve the activity of intestinal tract.
Example 2:
the difference from example 1 is that: the composition for regulating intestinal tracts comprises active components, wherein the active components comprise 40 parts by weight of inulin, 10 parts by weight of xylo-oligosaccharide, 15 parts by weight of oat dietary fiber, 10 parts by weight of semen cassiae extract and 12 parts by weight of lactobacillus reuteri fermentation product. In the initial curing step of the active ingredient, N2The pressure of (2) is 0.4 MPa. In the microencapsulation step, chitosan, sodium alginate and active swelling fiber are added and mixed evenly, and then the mixture is stood for 20min and then spray-dried.
In the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 40 meshes.
Example 3:
the difference from example 1 is that: aThe composition for regulating intestinal tracts comprises active components, wherein the active components comprise 60 parts by weight of inulin, 30 parts by weight of xylo-oligosaccharide, 8 parts by weight of oat dietary fiber, 15 parts by weight of semen cassiae extract and 5 parts by weight of lactobacillus reuteri fermentation product. In the initial curing step of the active ingredient, N2The pressure of (2) is 1 MPa. In the microencapsulation step, chitosan, sodium alginate and active swelling fiber are added and mixed evenly, and then the mixture is stood for 40min and then spray-dried.
In the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 40 meshes.
Example 4:
the difference from example 1 is that: the composition for regulating intestinal tracts comprises active components, wherein the active components comprise 60 parts by weight of inulin, 25 parts by weight of xylo-oligosaccharide, 15 parts by weight of oat dietary fiber, 15 parts by weight of semen cassiae extract and 5 parts by weight of lactobacillus reuteri fermentation product. In the initial curing step of the active ingredient, N2The pressure of (2) is 1 MPa. In the microencapsulation step, chitosan, sodium alginate and active swelling fiber are added and mixed evenly, and then the mixture is stood for 40min and then spray-dried.
In the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 80 meshes.
Example 5:
randomly dividing 10 ulcerative colitis patients into two groups, namely comparative examples 1,2,3,4 and 5, test groups 1,2,3,4 and 5, wherein one group is not provided with the composition of the invention, the other group is provided with the microcapsule (enteric coating) prepared in example 1, obtaining fresh fecal tissue 1g of the patients every ten days, adding 10mL of PBS buffer solution, mixing uniformly, centrifuging, separating supernatant and repeating for 3 times, collecting supernatant after 3 times of centrifugation, centrifuging at 13000r/min for 15min in a centrifuge, taking sediment and extracting genome DNA, designing specific primers of bifidobacterium and enterococcus and continuing to amplify, calculating the number of bacteria according to an amplification curve, and expressing the number of the bacteria as lgn/g, and testing results are shown in the following table:
as can be seen from the above table, after the administration of the microcapsules of example 1, the number of bifidobacteria in the intestines of 10 patients was gradually increased, the number of pathogenic enterococci was gradually decreased, and reached the level of normal persons after the administration of 20 days.
While one embodiment of the present invention has been described in detail, the description is only a preferred embodiment of the present invention and should not be taken as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (10)
1. The composition for facilitating intestinal regulation is characterized by comprising active components, wherein the active components comprise 40-60 parts by weight of inulin, 10-30 parts by weight of xylo-oligosaccharide, 8-15 parts by weight of oat dietary fiber, 10-15 parts by weight of semen cassiae extract and 5-12 parts by weight of lactobacillus reuteri fermentation product, and the method for obtaining the lactobacillus reuteri fermentation product comprises the following steps: obtaining the lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain the lactobacillus reuteri fermentation product.
2. The composition for assisting intestinal regulation according to claim 1, further comprising a membrane component, wherein the membrane component comprises chitosan and sodium alginate, and the membrane component is coated outside the active component to form a microcapsule.
3. The composition for aiding intestinal regulation according to claim 1, wherein the oat dietary fiber is expanded oat dietary fiber.
4. The preparation method of the composition for facilitating intestinal regulation is characterized by comprising the following steps:
1) extraction of lactobacillus reuteri fermentation: obtaining lactobacillus reuteri infected and surviving by salmonella enteritidis, and extracting secretion outside the lactobacillus reuteri after anaerobic fermentation of the obtained lactobacillus reuteri to obtain lactobacillus reuteri fermentation product;
2) primary curing of active ingredients: adding water into a mixture of 5-12 parts by weight of lactobacillus reuteri fermentation product and 10-30 parts by weight of xylo-oligosaccharide until the mixture is completely dissolved to obtain a first mixed solution, extruding and puffing 8-15 parts by weight of oat dietary fiber, drying to obtain puffed fiber, adding the first mixed solution into the puffed fiber, and adding N2Reacting under the environment until the reaction is dried to obtain active expanded fiber;
3) microencapsulation: and mixing the activated swelling fiber with 40-60 parts by weight of inulin, 10-15 parts by weight of cassia seed extract, chitosan, sodium alginate, water and an edible surfactant, and spray-drying to obtain the microcapsule beneficial to intestinal regulation.
5. The method for preparing a composition for facilitating intestinal tract regulation according to claim 4, wherein in the step of extracting the lactobacillus reuteri fermentation product, salmonella enteritidis and lactobacillus reuteri are simultaneously inoculated in a lactic acid bacteria culture medium for culture, then viable lactobacillus reuteri is separated from mixed bacteria, the separated lactobacillus reuteri is subjected to expanded culture and then filtered to obtain thalli, the obtained lactobacillus reuteri is subjected to anaerobic fermentation and then filtered to obtain thalli, a Tris-HCl buffer solution is added into the obtained thalli, a supernatant is obtained by centrifugation, and the filtrate is obtained by filtering the obtained supernatant with a semipermeable membrane.
6. The method for preparing a composition for intestinal tract regulation according to claim 5, wherein the harvested filtrate is freeze-dried and preserved in the extraction step of the Lactobacillus reuteri fermentation product.
7. The method for preparing a composition for regulating intestinal tract according to claim 4, wherein N is N in the initial curing step of the active ingredient2The pressure of the pressure sensor is 0.4-1 MPa.
8. The method for preparing the composition for facilitating intestinal tract regulation according to claim 4, wherein the step of adding raw materials in the step of microencapsulating comprises: adding inulin, oat dietary fiber, semen Cassiae extract and edible surfactant into water, mixing, adding chitosan, sodium alginate and active puffing fiber, and mixing.
9. The method for preparing the composition for regulating the intestinal tract according to claim 8, wherein in the microencapsulation step, chitosan, sodium alginate and active bulking fibers are added, mixed uniformly, and then are kept stand for 20-40 min and then are spray-dried.
10. The method for preparing a composition for regulating intestinal tract according to claim 9, wherein in the microencapsulation step, the particle size of the microcapsule obtained by spray drying is 40-80 meshes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393809.5A CN113080470A (en) | 2021-04-13 | 2021-04-13 | Composition beneficial to intestinal regulation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393809.5A CN113080470A (en) | 2021-04-13 | 2021-04-13 | Composition beneficial to intestinal regulation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113080470A true CN113080470A (en) | 2021-07-09 |
Family
ID=76676642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110393809.5A Pending CN113080470A (en) | 2021-04-13 | 2021-04-13 | Composition beneficial to intestinal regulation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113080470A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116875500A (en) * | 2023-07-07 | 2023-10-13 | 镇江远森医药科技有限公司 | Bioactive substance for regulating human body microecological balance prepared from Lactobacillus reuteri YSs207 and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249109A (en) * | 2008-03-14 | 2008-08-27 | 华侨大学 | Lactobacillus reuteri hollow micro-capsule and its preparing method |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
| CN108018235A (en) * | 2017-12-18 | 2018-05-11 | 江南大学 | A kind of high activity lactobacillus bacterium powder spray drying production technology and application |
| CN110810855A (en) * | 2018-08-14 | 2020-02-21 | 烟台药物研究所 | Dietary fiber composition with bowel relaxing function |
| CN111671791A (en) * | 2020-05-25 | 2020-09-18 | 中山大学 | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof |
-
2021
- 2021-04-13 CN CN202110393809.5A patent/CN113080470A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249109A (en) * | 2008-03-14 | 2008-08-27 | 华侨大学 | Lactobacillus reuteri hollow micro-capsule and its preparing method |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
| CN108018235A (en) * | 2017-12-18 | 2018-05-11 | 江南大学 | A kind of high activity lactobacillus bacterium powder spray drying production technology and application |
| CN110810855A (en) * | 2018-08-14 | 2020-02-21 | 烟台药物研究所 | Dietary fiber composition with bowel relaxing function |
| CN111671791A (en) * | 2020-05-25 | 2020-09-18 | 中山大学 | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 曹力 等: "乳酸杆菌的肠道调节作用及其在动物生产中应用的研究进展", 《中国畜牧兽医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116875500A (en) * | 2023-07-07 | 2023-10-13 | 镇江远森医药科技有限公司 | Bioactive substance for regulating human body microecological balance prepared from Lactobacillus reuteri YSs207 and application thereof |
| CN116875500B (en) * | 2023-07-07 | 2024-02-02 | 镇江远森医药科技有限公司 | Bioactive substance for regulating human body microecological balance prepared from Lactobacillus reuteri YSs207 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Extraction, purification, structural characterization, and gut microbiota relationship of polysaccharides: A review | |
| CN112370470B (en) | Microecological preparation for reconstructing intestinal microecology | |
| CN101687897A (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
| Du et al. | Recent progress in biological activities and health benefits of konjac glucomannan and its derivatives | |
| CN110959866A (en) | High-fiber chewable tablet containing probiotics and preparation method thereof | |
| CN112617182B (en) | Plant enzyme composition for weight management and preparation method thereof | |
| CN111436614A (en) | Probiotics delivery microcapsule based on mushroom soluble dietary fiber and preparation method | |
| CN115969957A (en) | Compound probiotic preparation for inflammatory bowel diseases and preparation method thereof | |
| CN113080470A (en) | Composition beneficial to intestinal regulation and preparation method thereof | |
| CN112970990A (en) | Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof | |
| CN116549494B (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| CN114521590A (en) | White kidney bean probiotic lipid-reducing tablet for blocking absorption of sugar and oil and preparation method thereof | |
| CN116035205A (en) | Probiotic composition for regulating metabolism and preparation method thereof | |
| CN114223795B (en) | Preparation method of probiotics feed for piglets | |
| CN114146120A (en) | Composition microcapsule for preventing and treating atrophic gastritis and preparation method thereof | |
| CN113143954A (en) | Novel citrus reticulata extract, preparation method thereof and medical application of novel citrus reticulata extract in improving intestinal flora | |
| CN112998231A (en) | Jelly capable of clearing intestines and expelling toxin and preparation method of jelly | |
| CN115944706B (en) | Traditional Chinese medicine probiotics compound with blood sugar reducing function and preparation method thereof | |
| Wang et al. | Effect of Lactobacillus fermentation on the structural feature, physicochemical property, and bioactivity of plant and fungal polysaccharides: A review | |
| CN112401242B (en) | Microecological preparation for reconstructing intestinal microecology and application thereof | |
| CN115814016B (en) | Composition of bacillus coagulans and garlic skin and application thereof | |
| CN114711435A (en) | Dietary fiber probiotic composition and preparation method thereof | |
| CN118104837A (en) | Preparation method of okra dietary fiber with prebiotic function | |
| CN118058476A (en) | Preparation method of oat dietary fiber with prebiotic function | |
| Liu et al. | Polysaccharides from Soybean Hulls and Their Functional Activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210709 |